Eli Lilly Collaborates with Amgen to Boost the Global Supply of its COVID-19 Therapies
Shots:
- The companies enter in a global Ab manufacturing collaboration to expedite the global supply of Lilly's COVID-19 therapies
- With the agreement- the two companies will have the ability to ramp up the production and serve more patients globally- once Lilly's Ab therapies prove successful in clinical testing and receive regulatory approval
- Lilly is currently evaluating multiple neutralizing Abs for the prevention and/or treatment of COVID-19 as either monothx. or as combination therapy. Amgen will leverage its technical expertise in antibody development and capabilities in the scale-up and manufacturing of complex biologics
Ref: PRNewswire | Image: Eli Lilly
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com